ATLAS fair value
ATLAS has no fair value for this stock today.
BioCardia stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
Prices as of Oct 27, 2026 · USD
ATLAS has no fair value for this stock today.
46%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives BioCardia a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $0.79 and $1.03; in 9 out of 10, between $0.62 and $1.31. Estimated annual volatility is 77%.
ATLAS does not publish a fair value for BCDA right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks BCDA has traded between $0.75 and $1.47. Today it is 37.5% below that high and 23% above its low.
Its beta is 0.55: it tends to move less than the market.
BioCardia, Inc. Common Stock represents an investment in BioCardia, a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
Want to see everything about BioCardia?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
BioCardia, Inc. Common Stock represents an investment in BioCardia, a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
46%: close to a coin flip. In half of the simulated outcomes, BCDA ends the month between $0.79 and $1.03.
BioCardia's market capitalization is $15.7M. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 77%. In a typical month, half of the outcomes end between $0.79 and $1.03.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy